Epinephrine exerts anticoagulant effects during human endotoxemia

van der Poll, T.; Levi, M.M.; Dentener, M.; Jansen, P.M.; Coyle, S.M.; Braxton, C.C.; Buurman, W.A.; Hack, C.E.; ten Cate, J.W.; Lowry, S.F.

DOI
10.1084/jem.185.6.1143

Publication date
1997

Published in
Journal of Experimental Medicine

Citation for published version (APA):
van der Poll, T., Levi, M. M., Dentener, M., Jansen, P. M., Coyle, S. M., Braxton, C. C., Buurman, W. A., Hack, C. E., ten Cate, J. W., & Lowry, S. F. (1997). Epinephrine exerts anticoagulant effects during human endotoxemia. Journal of Experimental Medicine, 185, 1143-1148. https://doi.org/10.1084/jem.185.6.1143
Brief Definitive Report

Epinephrine Exerts Anticoagulant Effects during Human Endotoxemia

By Tom van der Poll, Marcel Levi, Mieke Dentener, Patty M. Jansen, Susette M. Coyle, Carla C. Braxton, Wim A. Buurman, C. Erik Hack, Jan W. ten Cate, and Stephen F. Lowry

Summary

To determine the effect of a physiologically relevant elevation in the plasma concentrations of epinephrine on the activation of the hemostatic mechanism during endotoxemia, 17 healthy men were studied after intravenous injection of lipopolysaccharide (LPS, 2 ng/kg), while receiving a continuous infusion of epinephrine (30 ng/kg/min) started either 3 h (n = 5) or 24 h (n = 6) before LPS injection, or an infusion of normal saline (n = 6). Activation of the coagulation system (plasma concentrations of thrombin–antithrombin III complexes and prothrombin fragment F1+2) was significantly attenuated in the groups treated with epinephrine when compared with subjects injected with LPS only (P < 0.05). Epinephrine enhanced LPS-induced activation of fibrinolysis (plasma levels of tissue-type plasminogen activator and plasmin-α2-antiplasmin complexes; P < 0.05), but did not influence inhibition of fibrinolysis (plasminogen activator inhibitor type 1). In subjects infused with epinephrine, the ratio of maximal activation of coagulation and maximal activation of fibrinolysis was reduced by >50%. Hence, epinephrine exerts antithrombotic effects during endotoxemia by concurrent inhibition of coagulation, and stimulation of fibrinolysis. Epinephrine, whether endogenously produced or administered as a component of treatment, may limit the development of disseminated intravascular coagulation during systemic infection.

A systemic inflammatory response syndrome (SIRS) is frequently associated with disseminated intravascular coagulation, a serious complication that significantly contributes to organ injury and mortality (1). Enhanced release of epinephrine is part of the early host response to acute systemic infection and inflammation (2, 3). Although the role of epinephrine changes in substrate and energy metabolism, and cardiovascular control during SIRS has been widely recognized (2-4), knowledge of the in vivo effects of this catecholamine on activation of the hemostatic mechanism is limited.

It is conceivable that epinephrine influences coagulant and fibrinolytic pathways during SIRS for several reasons. Epinephrine has been reported to stimulate the release of tissue-type plasminogen activator (tPA) in humans in vivo (5, 6). Further, expression of tissue factor, the essential mediator of coagulation activation during SIRS (7, 8), can be inhibited in vitro by agents that elevate cellular cAMP (9, 10). Since β-adrenergic stimulation results in an increase in cellular cAMP concentrations (11, 12), it can be anticipated that epinephrine is able to influence coagulation. Knowledge of the hemostatic effect of epinephrine is important not only for the understanding of influences of endogenous adrenergic responses on the regulation of coagulation during SIRS, but also for the therapeutic use of catecholamines in patients with septic shock. Therefore, in the present study we sought to determine the effect of a constant intravenous epinephrine infusion on the activation of the hemostatic mechanism during low dose endotoxemia in normal humans.

Materials and Methods

Study Design and Subjects. This study was performed simultaneously with an investigation determining the effect of epineph-
raine on LPS-induced cytokine release (13). The study was approved by the Institutional Review Board, and written informed consent was obtained from all subjects before enrollment in the study. Nineteen male subjects, aged 28 ± 1 (mean ± SE) yr, were admitted to the Adult Clinical Research Center of The New York Hospital-Cornell University Medical Center for 4 d (day 0 to day 3). On day 1, 8 subjects were started on a constant intravenous infusion of epinephrine (30 ng/kg min; Parke-Davis, Morris Plains, NJ), starting at 9:00 AM. On day 2, arterial blood was obtained at 6:00 AM (i.e., directly before the start of the infusion of epinephrine in the EPI-3 group or the start of saline infusion in the LPS group) (t = −3 h), directly before the injection of LPS (t = 0 h), and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 h thereafter. All blood samples were centrifuged at 4°C for 20 min at 1,600 g and plasma was stored at −70°C until assayed.

Activation of the coagulation system was determined in citrated plasma by measurements of prothrombin fragment F1 + 2 and thrombin–antithrombin III (TAT) complexes (ELISAs Behringwerke A.G., Marburg, Germany). Activation of fibrinolysis was determined in citrated plasma by measurements of tPA antigen and plasminogen activator inhibitor type 1 (PAI-1) antigen (ELISAs Innogenetics, Nijmegen, The Netherlands). PAI-1 activity by amidolytic assay (Chromogenix, Mölndal, Sweden), and plasmin-α2-antiplasmin (PAP) complexes (8). Soluble E-selectin levels were measured in K2-EDTA anticoagulated plasma by ELISA (14).

Statistical Analysis. All values are given as means ± SEM. Differences within groups were analyzed by one-way analysis of variance. Differences between groups were analyzed by two-way analysis of variance (interaction treatment and time). Two sample comparisons were performed by Wilcoxon test. P < 0.05 was considered to represent a statistically significant difference.

Results

A diversion of coagulation. Infusion of epinephrine only (day 1) did not influence the plasma concentrations of F1 + 2 or TAT complexes (data not shown). Injection of LPS induced transient rises in plasma F1 + 2 and TAT complexes, peaking after 4 h (4.61 ± 1.03 nmol/l and 31.9 ± 4.7 ng/ml, respectively; both P < 0.05 versus time). Both EPI-3 and EPI-24 strongly attenuated LPS-induced coagulation activation (Fig. 1). In the EPI-3 group, peak concentrations of F1 + 2 and TAT complexes were 1.88 ± 0.34 nmol/l and 16.5 ± 5.6 ng/ml, respectively, in the EPI-24 group, 2.25 ± 0.6 ng/ml, 9.9 ± 0.9 ng/ml, respectively. The injection of LPS was performed on day 1, venous blood was obtained before the start of infusion with epinephrine (t = 0 h), and at 1, 2, 4, and 8 h thereafter. On day 2, arterial blood was obtained at 6:00 AM (i.e., directly before the start of the infusion of epinephrine in the EPI-3 group or the start of saline infusion in the LPS group) (t = −3 h), directly before the injection of LPS (t = 0 h), and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 h thereafter. All blood samples were centrifuged at 4°C for 20 min at 1,600 g and plasma was stored at −70°C until assayed.

Figure 1. Epinephrine inhibits LPS-induced coagulation activation. Mean (± SE) plasma concentrations of prothrombin fragment F1 + 2 and TAT complexes after intravenous injection of LPS (2 ng/kg, lot EC-5) at t = 0. LPS = subjects injected with LPS only (n = 6); EPI-3 = subjects infused with epinephrine (30 ng/kg min) from t = −3 h to 6 h (n = 5); EPI-24 = subjects infused with epinephrine (30 ng/kg min) from t = −24 h to 6 h (n = 6). Both EPI-3 and EPI-24 attenuated LPS-induced increases in F1 + 2 and TAT complexes (P < 0.05 versus LPS only).

Table 1. Effect of Epinephrine on Fibrinolysis

| Time | tPA antigen | PAP complexes | PAI-1 antigen | PAI-1 activity |
|------|-------------|---------------|---------------|---------------|
| h    | ng/ml       | nmol/l        | ng/ml         | ng/ml         |
| 0    | 3.5 ± 0.6   | 5.9 ± 1.1     | 7.1 ± 1.0     | 4.0 ± 0.8     |
| 1    | 11.6 ± 1.8  | 14.4 ± 2.3    | 7.3 ± 0.8     | 4.4 ± 0.9     |
| 2    | 6.1 ± 1.7   | 9.9 ± 0.9     | 8.6 ± 0.6     | 4.9 ± 0.8     |
| 4    | 4.6 ± 1.3   | 8.1 ± 0.8     | 5.6 ± 0.8     | 5.0 ± 0.8     |
| 8    | 3.3 ± 0.6   | 7.5 ± 1.0     | 7.9 ± 0.9     | 7.1 ± 1.0     |
| 21   | 3.6 ± 0.6   | 6.3 ± 1.1     | 10.6 ± 1.3    | 4.5 ± 0.7     |
| 24   | 3.2 ± 0.6   | 6.1 ± 0.9     | 10.6 ± 1.4    | 5.3 ± 0.5     |
| P vs. time | P < 0.05 | P < 0.05 | P < 0.05 | NS |

Data are mean ± SE of eight subjects receiving a continuous 24-h intravenous infusion of epinephrine (30 ng/kg min) starting at t = 0. NS, nonsignificant.
Activation of Fibrinolysis. Infusion of epinephrine only (day 1) modestly stimulated fibrinolysis, as reflected by transient rises in the plasma concentrations of tPA and PAP complexes. Epinephrine also caused a relatively late increase in the plasma levels of PAI-1 antigen (Table 1).

Administration of LPS resulted in a marked activation of fibrinolysis, followed by a strong inhibition coinciding with maximal coagulation activation (Fig. 2). Peak levels of indexes of fibrinolytic activation were found after 1.5 to 2 h, i.e., before maximal coagulation activation: tPA antigen (32.1 ± 2.0 ng/ml) and PAP complexes (33.9 ± 4.5 nmol/l) (both P < 0.05 versus time). Peak levels of indexes of inhibition of fibrinolysis were found thereafter, i.e., after 4 h: PAI-1 antigen (140.7 ± 9.9 ng/ml) and PAI activity (42.0 ± 3.2 ng/ml) (both P < 0.05 versus time). Both EPI-3 and EPI-24 enhanced LPS-induced activation of fibrinolysis (Fig. 2). In the EPI-3 group, peak levels of tPA antigen and PAP complexes were 47.8 ± 2.6 ng/ml and 50.2 ± 5.4 nmol/l (both P < 0.05 versus LPS only), respectively. In the EPI-24 group, these levels were 44.2 ± 2.7 ng/ml and 50.6 ± 7.3 nmol/l (both P < 0.05 versus LPS only), respectively. By contrast, neither EPI-3 nor EPI-24 influenced inhibition of fibrinolysis after injection of LPS, as reflected by unchanged increases in the plasma levels of PAI-1 antigen and PAI activity in the three study groups (Fig. 2).

Ratio of Coagulation and Fibrinolysis. Since epinephrine appeared to inhibit coagulation and enhance fibrinolysis, we were interested in the effect of epinephrine on the balance between coagulation and fibrinolysis. For this purpose we calculated the ratio of the peak plasma levels of TAT complexes and PAP complexes. Both EPI-3 and EPI-24 reduced this ratio to <50% of the ratio found after administration of LPS only (P < 0.05; Table 2).

Table 2. The Effect of Epinephrine on the Coagulation/Fibrinolysis Balance

| Subject | LPS | EPI-3 | EPI-24 |
|---------|-----|-------|-------|
| 1       | 0.61| 0.69  | 0.54  |
| 2       | 0.83| 0.49  | 0.51  |
| 3       | 1.17| 0.18  | 0.14  |
| 4       | 0.89| 0.42  | 0.64  |
| 5       | 1.07| 0.38  | 0.29  |
| 6       | 1.08| –     | 0.25  |
| Mean ± SE | 0.94 ± 0.08 | 0.43 ± 0.08* | 0.40 ± 0.08* |

Data are ratios of peak plasma levels of TAT complexes and PAP complexes, reflecting activation of coagulation and fibrinolysis respectively. LPS, subjects injected with LPS only; EPI-3, subjects infused with epinephrine (30 ng/kg/min) from t = −3 h to 6 h; EPI-24, subjects infused with epinephrine (30 ng/kg/min) from t = −24 h to 6 h. *P < 0.05 versus LPS.

Figure 2. Epinephrine enhances LPS-induced fibrinolytic activation, while not influencing inhibition of fibrinolysis. Mean (± SE) plasma concentrations of tPA antigen, PAP complexes, PAI-1 antigen, and activity after intravenous injection of LPS (2 ng/kg, lot EC-5) at t = 0. LPS = subjects injected with LPS only (n = 6); EPI-3 = subjects infused with epinephrine (30 ng/kg/min) from t = −3 h to 6 h (n = 5); EPI-24 = subjects infused with epinephrine (30 ng/kg/min) from t = −24 h to 6 h (n = 6). EPI-3 and EPI-24 enhanced LPS-induced increases in tPA and PAP complexes (P < 0.05 versus LPS only), while not significantly changing PAI-1 antigen or activity.
Epinephrine Exerts Anticoagulant Effects during Endotoxemia

The gradual increase in PAI-1 antigen during infusion of epinephrine was mediated via an effect on the cytokine system. Indeed, TNF is not necessary for activation of coagulation during low grade endotoxemia (20), and IL-10 levels were unaltered in the EPI-24 group, whereas this group showed a similar inhibition of coagulation as the EPI-3 group (13). Further, neither epinephrine infusion influenced LPS-induced release of IL-6 (13), a cytokine that appears to play an important role in LPS-induced coagulation activation (21).

Continuous infusion of epinephrine per se (day 1) was associated with a transient activation of the fibrinolytic system. Earlier studies demonstrated tPA release after short-term exposure of humans to epinephrine (5, 6), which likely reflects a direct effect of epinephrine on the vascular endothelium (22). Additionally, epinephrine potentiated the release of tPA in response to injection of LPS. It should be noted that epinephrine did not cause a general endothelial cell activation, since the release of soluble E-selectin, a molecule that is shed by the vascular endothelium upon activation (14, 23), was inhibited in the EPI-3 and EPI-24 groups. Epinephrine did not influence LPS-induced release of the main inhibitor of plasminogen activation, PAI-1. The gradual increase in PAI-1 antigen during infusion of epinephrine only (day 1) likely reflects a modest acute phase protein response induced by this hormone, considering that...
PAI-1 behaves as an acute phase protein during inflammation (24), and that other acute phase proteins also gradually increased during epinephrine infusion (data not shown).

Systemic infection and acute injury lead to the activation of multiple host mediator systems. We demonstrate here that a physiologically relevant elevation in the plasma levels of epinephrine markedly influences the activation of hemo-

static mechanism during endotoxemia in humans. The anticoagulant effect of epinephrine represents a property of this catecholamine not previously recognized that may be important for the understanding of the complex agonistic and antagonistic interactions between various mediator systems involved in the pathogenesis of disseminated intravascular coagulation in acutely ill patients.

References

1. Levi, M., H. ten Cate, T. van der Poll, and S.J.H. van Deventer. 1993. New insights in the pathogenesis of disseminated intravascular coagulopathy in sepsis. JAMA (J. Am. Med. Assoc.). 270:975–979.
2. Frayn, K.N. 1986. Hormonal control of metabolism in trauma and sepsis. Clin. Endocrinol. 24:577–599.
3. Tracey, K.J., S.F. Lowry, T.J. Fahey III, J. Albert, Y. Fong, D. Hesse, B. Butler, K.R. Manogue, S. Calvano, H. Wei et al. 1987. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gynecol. Obstet. 164:415–422.
4. Fellows, I.W., T. Bennett, and L.A. MacDonald. 1985. The effect of adrenaline upon cardiovascular and metabolic functions in man. Clin. Sci. 69:215–222.
5. Chandler, W.I., R.C. Veith, G.W. Fellingham, W.C. Levy, R.S. Schwartz, M.D. Cerquera, S.F. Kahn, V.G. Larson, K.C. Cain, J.C. Beard et al. 1987. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J. Am. Coll. Cardiol. 19:1412–1420.
6. Chandler, W.I., W.C. Levy, R.C. Veith, and J.S. Stratton. 1993. A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion, and endurance training. Blood. 81:3293–3302.
7. Taylor Jr., F.B., A. Chang, W. Ruff, J.H. Morrissey, L. Hinshaw, R. Catlett, K. Blick, and T.S. Edgington. 1991. Lethal endotoxin shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock. 33:127–134.
8. Levi, M., H. ten Cate, K.A. Bauer, T. van der Poll, T.S. Edgington, H.R. Bülter, S.J.H. van Deventer, C.E. Hack, J.W. ten Cate, and R.D. Rosenberg. 1994. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J. Clin. Invest. 93:114–120.
9. Crutchley, D.J., and M.J. Hirsch. 1991. The stable prosta-
cyclin analog, iloprost, and prostaglandin E1, inhibit monocyte procoagulant activity in vitro. Blood. 78:382–386.
10. Ollivier, V., S. Housaye, C. Ternisien, A. Leon, H. de Verneuil, C. Elbim, N. Ackman, T.S. Edgington, and D. de Prost. 1993. Endotoxin-induced tissue factor messenger RNA in human monocytes is negatively regulated by a cyclic AMP-dependent mechanism. Blood. 81:973–979.
11. Verghese, M.W., and R. Snyderman. 1983. Hormonal activation of adenylate cyclase in macrophage membranes is regulated by guanine nucleotides. J. Immunol. 130:869–873.
12. Severn, A., N.T. Rapson, C.A. Hunter, and F.Y. Liew. 1992. Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J. Immunol. 148:3441–3445.
13. van der Poll, T., S.M. Coyle, K. Barbosa, C.C. Braxton, and S.F. Lowry. 1996. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J. Clin. Invest. 97:713–719.
14. Leeuwenberg, J.F., E.F. Smeets, J.J. Neefjes, M.A. Shaffer, T. Cinek, T.M. Jeunhomme, T.J. Ahern, and W.A. Buurman. 1992. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 77:543–549.
15. van der Poll, T., J. Jansen, E. Endert, H.P. Sauerwein, and S.J.H. van Deventer. 1994. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. In Vitro Immune. 62:2046–2050.
16. Strassmann, G., V. Patil-Koota, F. Finkelman, M. Fong, and T. Kambayashi. 1994. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J. Exp. Med. 180:2365–2370.
17. van der Poll, T., S.M. Coyle, M. Levi, M.A. Boermeester, C.C. Braxton, P.M. Jansen, C.E. Hack, and S.F. Lowry. 1996. Fat emulsion infusion potentiates coagulation activation during human endotoxemia. Thromb. Haemostas. 75:83–86.
18. Nawroth, P.P., and D.M. Stern. 1986. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:740–745.
19. Pradier, O., C. Gérard, A. Delvaux, M. Lybin, D. Abramowicz, P. Capel, T. Velu, and M. Goldman. 1993. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur. J. Immunol. 23:2700–2703.
20. van der Poll, T., M. Levi, S.J.H. van Deventer, H. ten Cate, B.L. Haagmans, B.J. Biemond, H.R. Bülter, C.E. Hack, and T.J. Ahern. 1992. Lethal endotoxin shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock. 33:127–134.

Supports by RO 1 GM 34695, and RR 0047 from the U.S. Public Health Service. Tom van der Poll is a fellow of the Royal Netherlands Academy of Arts and Sciences.

Address correspondence to Stephen F. Lowry, M.D., University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, Department of Surgery, One Robert Wood Johnson Place–CN19, New Brunswick, NJ 08903-0019.

Received for publication 3 September 1996 and in revised form 21 January 1997.
J.W. ten Cate. 1994. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 83: 446–451.

21. van der Poll, T., M. Levi, C.E. Hack, H. ten Cate, S.J.H. van Deventer, A.J.M. Eerenberg, E.R. de Groot, J. Jansen, H. Gallati, H.R. Böller et al. 1994. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med. 179:1253–1259.

22. Kjaelgaard, A., and M. Kjaelgaard. 1986. In vitro stimulation of plasminogen activator release from vein walls by adrenaline. J. Clin. Pathol. 39:1241–1244.

23. Newman, W., L.D. Beall, C.W. Carson, G.G. Hunder, N. Graben, Z.I. Randhawa, T.V. Gopal, J. Wiener-Kronisch, and M.A. Matthay. 1993. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J. Immunol. 150:644–654.

24. De Boer, J.P., J.J. Abbink, M.C. Brouwer, C. Meijer, D. Roem, G.P. Voorn, J.W.J. Lambers, J.A. van Mourik, and C.E. Hack. 1991. PAI-1 synthesis in the human hepatoma cell line Hep G2 is increased by cytokines. Evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb. Haemostas. 65:181–185.